Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. - Wikidata - awgldk - TriplyDB

Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.

Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.

http://www.wikidata.org/entity/Q35290298

about

Challenges and opportunities for the implementation of virological testing in resource-limited settings Using HIV surveillance data to monitor missed opportunities for linkage and engagement in HIV medical care.Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.Cumulative HIV viremia and non-AIDS-defining malignancies among a sample of HIV-infected male veterans Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health setting When to start antiretroviral therapy: the need for an evidence base during early HIV infection Traditional risk factors are more relevant than HIV-specific ones for carotid intima-media thickness (cIMT) in a Brazilian cohort of HIV-infected patients.High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention.Retained in HIV Care But Not on Antiretroviral Treatment: A Qualitative Patient-Provider Dyadic Study Late presentation to HIV/AIDS testing, treatment or continued care: clarifying the use of CD4 evaluation in the consensus definition.Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study.HIV RNA suppression and immune restoration: can we do better?Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort.Viral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in Ghana HIV Infection Is Not Associated with Carotid Intima-Media Thickness in Brazil: A Cross-Sectional Analysis from the INI/ELSA-Brasil Study.Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.The Effects of Viral Load Burden on Pregnancy Loss among HIV-Infected Women in the United States.mTOR activity in AIDS-related diffuse large B-cell lymphoma.Specimen origin, type and testing laboratory are linked to longer turnaround times for HIV viral load testing in Malawi Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy.Measuring retention in HIV care: the elusive gold standard.Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study.Reevaluating Cumulative HIV-1 Viral Load as a Prognostic Predictor: Predicting Opportunistic Infection Incidence and Mortality in a Ugandan Cohort.Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy.Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings?Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death.Association of early HIV viremia with mortality after HIV-associated lymphoma.Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size Dynamics of viremia in primary HIV-1 infection in Africans: insights from analyses of host and viral correlates.Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy.Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012-2013.

P2860

Q27026923-365D5C69-4F9D-4DE1-933D-8065591A19DF Q30572715-695FCDD5-0C32-480A-968B-242255BCC2D9 Q33579962-7B7C9765-6F01-4A5B-AC92-EC9F14F189A0 Q33598231-14BA6F62-C7A9-4B5D-BFAF-5B6EC7097269 Q33649200-4A2B971E-A6CA-423F-B402-83B3D62EB15B Q33696149-C35FA525-1A8B-4D5B-88A8-866071ACCA0A Q33798584-DC7B826A-3208-42A2-A396-612298CCB165 Q33880782-BB8B3BE5-FB02-4B5E-A86D-E62F2AF4F027 Q34173349-C69122A3-0D53-4483-A1B8-756BCFA618D2 Q34379806-BD696941-4B49-413A-A963-6268EE24F87A Q34642257-F566A716-7716-4B5E-BDAA-3408038B431E Q34773308-BB5ADF63-FB70-400B-AF71-ABA797F5D9E1 Q35097454-E2270880-AB7B-43B5-8CD8-34B45AA7E2A1 Q35119753-F2E25B78-B22E-437E-AD08-1D9BF4049053 Q35613083-2980D430-1EE8-4568-869B-D8B50F12184B Q35742805-844E9288-A142-4EF0-9CDD-939DC9DCB038 Q35770832-F8EC5D68-CE6B-49D7-8DEA-1DC6EDF182D9 Q35782774-2ED3488B-98D1-4A77-B3E5-E8DA1813ABCB Q35867173-3440E37F-BAD7-4CC6-8886-CCBFE143669C Q35873534-A3DF41BC-480E-4A7B-994F-FC4502648385 Q35914071-B9263ADA-0C70-44A1-B2D9-FEBA1CCE093C Q36071230-858F0AE7-850F-40C9-97C2-767E3F607696 Q36109276-6FC368A6-D269-435D-8801-0577AFA8D3AA Q36259895-8E82FFD5-DCEB-41A0-AFF7-8343BC5F70DA Q36278593-D363F0A9-6CAC-4B2D-9D50-C8FF6017EC25 Q36289976-CF46AE5B-98EC-47CF-BCBF-68EA2016D61C Q36356427-C1939D95-3D17-4C1C-BEDB-4AF8EB013F2A Q36428000-2DBF6DAF-A068-4368-AFFC-B65206723BF6 Q36634843-D6932AE2-364B-4CF7-8A15-D9D477B64037 Q37056879-D320A4EF-D0D3-40D1-B192-C2623065020E Q37077610-8D3FFF22-DD69-4B55-B9C8-78AC48360EEB Q37111627-A77BA86E-B399-428A-8EF7-875FC9FB9E79 Q37167877-396C714F-F68C-449D-AB64-9652D562EA12 Q37171460-DDF83A8C-6105-4701-943F-56480C768351 Q37187501-FA76F8A3-319E-43F4-A563-B4D7E708FCA5 Q37597093-A25C39DF-5436-4839-97C3-6878C98FC216 Q37695051-F81BC5BF-4BEC-4A6D-BDCA-9D0BA3931A3F Q38876754-40E0E4F4-5853-4123-93F3-D7609A9FBF9E Q39375437-32834F74-528E-4842-8845-3F083AF30362 Q39643842-DC0B9E03-5595-4F73-ABD5-A6006E6D1822

P2860

Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.

http://www.wikidata.org/entity/Q35290298

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Viremia copy-years predicts mo ...... iating antiretroviral therapy.

@ast

Viremia copy-years predicts mo ...... iating antiretroviral therapy.

@en

type

label

Viremia copy-years predicts mo ...... iating antiretroviral therapy.

@ast

Viremia copy-years predicts mo ...... iating antiretroviral therapy.

@en

prefLabel

Viremia copy-years predicts mo ...... iating antiretroviral therapy.

@ast

Viremia copy-years predicts mo ...... iating antiretroviral therapy.

@en

P1433

Q35290298-26735030-AE11-4C35-8E5C-A0F23FBAE28A

P1476

Q35290298-0BAFE8C9-11A0-43E9-8611-528AAC5CE47E

P2093

Q35290298-12EFE070-BBC4-4591-AC5C-88436E238FE9

Q35290298-4CF9C4D2-E86B-4B3A-8265-33D2982F76B4

Q35290298-6D9EE563-00BF-44E4-827C-1688F297C373

Q35290298-70460868-E489-457A-841A-7F3016396538

Q35290298-76815323-484F-4523-8B6F-62909E8FB132

Q35290298-827A246F-7AD8-46A7-8F91-10B58274BCA3

Q35290298-D90289E0-67EB-4349-8FC3-E7B3D3728C5D

Q35290298-E2AF9EE2-6F1A-430E-BCAB-73D076018173

Q35290298-ECBFE39A-976B-4542-8AC9-3F9E71BB1FA3

P2860

Q35290298-0667D72E-45A1-411D-8C52-1F6943082D22

Q35290298-1035852B-B9E3-48B7-9F7E-11F5AEA56E93

Q35290298-12D30805-FE9B-4B89-BFD8-66D02099E475

Q35290298-16C673FB-3680-4B6E-91DA-3FC3D9C95193

Q35290298-38D0E386-A959-4E5B-83BA-C9CD45253850

Q35290298-39B12E68-875E-4B0D-B968-1F6E0071B935

Q35290298-3BEF4F06-7CFD-490C-9BB6-059635271F22

Q35290298-3EA2F512-1798-4698-A11D-A2E80097822C

Q35290298-4263C461-D803-43BC-88D0-1E0F79C4E081

Q35290298-5991BACF-55ED-4BAA-B19D-3007A55705E2

P304

Q35290298-A9A1A9C7-9A2C-4739-A5B0-22F74F9A85E0

P31

Q35290298-6F4AF0C7-6838-43B4-8C30-8A2D8436A27B

P356

Q35290298-2BE81D84-B5CA-4199-8FD2-5FAA81F7A880

P407

Q35290298-7D8C62B6-CA22-42AB-9BA0-22642E01A5C9

P433

Q35290298-A59DD936-9A2C-4487-A6C9-91B69E8D65EF

P478

Q35290298-7AB3892B-60E7-46C5-BEEE-E05381FC9772

P50

Q35290298-6E974314-0497-4193-9C0D-3F53E812BAD0

Q35290298-D46618CB-AD3C-4F7E-85BC-002C3FD36B5F

Q35290298-F78A0090-F2CB-4E6C-B3D1-22C28FF610B8

P577

Q35290298-ABCAA3D0-FB7C-46DA-A43A-370A6979BE13

P5875

Q35290298-21E802B5-38D0-421A-8B07-F43FB1887504

P698

Q35290298-3CC1C8CB-F13A-4357-BB9D-B6DA07622BCB

P921

Q35290298-61688FE4-B14D-4116-BB24-3BF691D7BCF7

P932

Q35290298-477FCADE-5EAA-4118-A1BA-96E1FE9024AB

P356

P1433

Clinical Infectious Diseases

P1476

Viremia copy-years predicts mo ...... iating antiretroviral therapy.

@en

P2093

Bryan Lau

http://www.w3.org/2001/XMLSchema#string

Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort Study

http://www.w3.org/2001/XMLSchema#string

Heidi M Crane

http://www.w3.org/2001/XMLSchema#string

James H Willig

http://www.w3.org/2001/XMLSchema#string

Mari M Kitahata

http://www.w3.org/2001/XMLSchema#string

Michael J Mugavero

http://www.w3.org/2001/XMLSchema#string

Michael S Saag

http://www.w3.org/2001/XMLSchema#string

Richard D Moore

http://www.w3.org/2001/XMLSchema#string

Stephen R Cole

http://www.w3.org/2001/XMLSchema#string

P2860

High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

Marginal structural models and causal inference in epidemiology

CD4+ count-guided interruption of antiretroviral treatment

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.

P304

927-935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIR526

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Sonia Napravnik

P577

2011-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51618009

http://www.w3.org/2001/XMLSchema#string

P698

21890751

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3189165

http://www.w3.org/2001/XMLSchema#string